SequelSEC

Jaguar Health, Inc. JAGX

Pharmaceutical Preparations · CIK 0001585608 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.22M
Fiscal year ended 2026-06-30
Operating income
-$7.60M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Jaguar Health, Inc. (JAGX) reported revenue of $1.22M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Jaguar Health, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Jaguar Health, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.22M$20.27M$3.24M$3.08M$2.98M$2.21M$3.51M$3.11M$2.72M$2.35M
Cost of revenue$1.03M$1.16M$2.20M$532.00K$527.00K$515.00K$557.00K$541.00K$427.00K$430.00K
Gross profit$194.00K$19.11M$1.04M$2.55M$2.45M$1.70M$2.95M$2.57M$2.29M$1.92M
Operating income-$7.60M$10.18M-$21.24M-$7.24M-$8.01M-$9.42M-$8.16M-$7.26M-$7.20M-$8.22M
Net incomeUnavailableUnavailable-$23.20M-$9.50M-$10.41M-$10.46M-$9.92M-$9.85M-$9.49M-$9.23M
Research & development$3.34M$3.93M$14.31M$3.66M$3.26M$3.73M$4.53M$4.04M$3.65M$4.31M
Weighted-average diluted sharesshares 809.12Kshares 515.79KUnavailableshares 1.51MUnavailableUnavailableUnavailableUnavailableshares 3.57MUnavailable
Pretax income-$12.80M$8.72M-$23.19M-$9.65M-$10.56M-$10.60M-$10.23M-$10.02M-$9.63M-$9.37M
Income tax expense$0$0UnavailableUnavailable$0$0$0$0$0$0
Diluted EPS$-15.70$-13.60Unavailable$-6.28$-358.94$-584.45Unavailable$-26.29$-2.66$-87.12
Selling, general & administrative$4.46M$5.00M$7.16M$6.13M$7.19M$7.39M$6.58M$5.79M$5.84M$5.82M
General & administrative$4.45M$4.11M$4.89M$4.13M$4.73M$4.90M$3.86M$3.78M$4.31M$4.38M
Selling & marketing$5.00K$896.00K$2.28M$2.00M$2.47M$2.49M$2.72M$2.01M$1.52M$1.44M

Balance

Jaguar Health, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$3.79M$7.28M$968.00K$3.53M$2.21M$5.69M$8.00M$13.27M$16.05M$11.67M
Total assets$34.19M$37.43M$38.32M$49.47M$48.27M$51.46M$53.42M$58.47M$61.46M$55.39M
Current assets$17.53M$20.21M$20.34M$29.40M$27.90M$30.44M$32.20M$36.64M$40.11M$33.71M
Total liabilities$29.27M$53.19M$57.01M$45.11M$41.39M$48.14M$44.45M$42.88M$42.40M$41.09M
Current liabilities$25.38M$40.69M$40.65M$36.12M$29.22M$28.21M$19.70M$19.87M$19.13M$17.81M
Total equity incl. NCI$4.92M-$15.75M-$18.69M$4.36M$6.88M$830.00K$6.49M$13.10M$16.58M$11.82M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable$0$0$2.48M$2.48M$2.48M$2.48M$2.48M
Inventory$7.32M$7.82M$8.60M$10.63M$10.72M$10.56M$10.34M$9.67M$9.56M$9.02M
Accounts receivable$8.00K$68.00K$1.52M$1.44M$1.17M$1.22M$1.53M$1.25M$1.30M$1.51M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.79M$4.96M$8.69M$8.44M$6.62M$7.03M$5.29M$4.55M$4.09M$3.32M

Cash flow

Jaguar Health, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$5.34M$8.83M-$5.49M-$4.69M-$6.20M-$7.31M-$7.83M-$6.34M-$8.17M-$7.05M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0UnavailableUnavailable
Investing cash flowUnavailableUnavailable$13.00KUnavailableUnavailableUnavailable-$215.00K$0UnavailableUnavailable
Financing cash flow$1.86M-$6.62M$9.79M$6.26M$2.66M$4.97M$2.83M$3.53M$12.57M$12.27M
Net change in cash-$3.47M$2.23M$4.30M$1.32M-$3.48M-$2.31M-$5.27M-$2.78M$4.38M$5.20M
Stock-based compensation$171.00K$155.00K$116.00K$135.00K$279.00K$301.00K$372.00K$305.00K$383.00K$581.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$473.00K$473.00K$477.00K$479.00K$478.00K$479.00K$478.00K$474.00K$447.00K$501.00K

Derived

Jaguar Health, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$7.83M-$6.34MUnavailableUnavailable
Gross margin15.8%94.3%32.0%82.7%82.3%76.7%84.1%82.6%84.3%81.7%
Operating margin-620.2%50.2%-656.6%-234.8%-268.8%-425.5%-232.5%-233.7%-264.5%-349.4%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-223.0%-204.0%UnavailableUnavailable
SBC / revenue14.0%0.8%3.6%4.4%9.4%13.6%10.6%9.8%14.1%24.7%
Current ratio0.69x0.50x0.50x0.81x0.95x1.08x1.63x1.84x2.10x1.89x
Revenue YoY growth-58.9%815.6%-7.8%-0.8%9.5%-5.8%52.6%10.5%UnavailableUnavailable
Net marginUnavailableUnavailable-717.2%-308.2%UnavailableUnavailable-282.7%-317.1%-348.8%-392.4%
R&D / revenue272.3%19.4%442.4%118.7%109.6%168.5%129.2%130.1%134.3%183.4%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable0.0%0.0%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable0.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JAGX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-07View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2020-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2020-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.